Ku EJ, et al. - In patients with ineffectively controlled type 2 diabetes (T2D), researchers assessed the efficacy and safety of two distinct sodium-glucose co-transporter 2 (SGLT2) inhibitors, empagliflozin vs dapagliflozin, as part of a quadruple oral antidiabetic agents (OADs) regimen. This investigation was conducted in T2D subjects with glycated hemoglobin (HbA1c) from 7.5-12.0% with metformin, glimepiride and dipeptidyl peptidase-4 inhibitors. For this open-labeled, prospective, 52-week study, patients received either empagliflozin (25 mg/day) or dapagliflozin (10 mg/day). In T2D patients who are treated with three other OADs, SGLT2 inhibitors could be effectively used as a fourth OAD. More specifically, in reducing HbA1c and improving other cardiometabolic parameters, empagliflozin was more effective than dapagliflozin.